Unfractionated Heparin Use After Percutaneous Coronary Intervention: Results of a Trial with a Vascular Ultrasound Endpoint

Juergens, C.; Crozier, John; Robinson, JH; Lo, S.; French, John K.; Leung, Dominic Y.

doi:10.1016/j.hlc.2007.07.011

Heart, Lung and Circulation

2008

DOI: 10.1016/j.hlc.2007.07.011

|View full text |Cite

Unfractionated Heparin Use After Percutaneous Coronary Intervention: Results of a Trial with a Vascular Ultrasound Endpoint

C. Juergens

John Crozier

JH Robinson

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

2011

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LMWH should be preferred over UFH, if clinically feasible, due to the relatively lower risk of HIT. Routine use of heparin following PCI is not recommended 77–84 . When there is an indication for heparin following PCI, such as residual coronary thrombus, significant residual dissection, left ventricular thrombus, atrial fibrillation, or suboptimal PCI result, LMWH should be used.…”

mentioning

confidence: 99%

Thrombocytopenia following Percutaneous Coronary Intervention

Shenoy

Harjai

2011

Journal of Interventional Cardiology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Thrombocytopenia following Percutaneous Coronary Intervention

Shenoy

Harjai

2011

Journal of Interventional Cardiology

View full text Add to dashboard Cite

show abstract

Safety and Efficacy of Prolonged Use of Unfractionated Heparin After Percutaneous Coronary Intervention

Singh¹,

Arora²,

Singh³

et al. 2010

American Journal of Therapeutics

View full text Add to dashboard Cite

The current guidelines for percutaneous coronary intervention do not address the prolonged postprocedural use of unfractionated heparin (UFH) to prevent acute occlusion. However, recently published small studies have yielded mixed results, leaving the question unanswered. Hence, we performed a meta-analysis of the existing evidence to assess the safety and efficacy of prolonged infusion of UFH after percutaneous coronary intervention. A systematic review of literature revealed seven studies involving 2412 patients. End points analyzed were ischemic complications (acute closure, myocardial infarction, and repeat revascularization) and major vascular complications (hematoma, arteriovenous fistula, pseudoaneurysm, and retroperitoneal bleed). Because the studies were homogenous for outcomes, combined relative risks across all the studies and the 95% confidence intervals were computed using the Mantel-Haenszel fixed-effect model. A two-sided alpha error <0.05 was considered to be statistically significant. There were no significant differences in patient demographics between both groups. Compared with placebo, the risk of major vascular complication was significantly higher in patients getting postprocedural UFH for prolonged hours (relative risk, 2.24; confidence interval, 1.68-3.48; P = 0.001). However, the risk of ischemic complications was similar in both groups (relative risk, 0.95; confidence interval, 0.46-1.96; P = 0.89). The meta-analysis suggests that routine infusion of UFH after uncomplicated percutaneous coronary intervention may result in increased vascular complications without any reduction in incidence of ischemic complications.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Unfractionated Heparin Use After Percutaneous Coronary Intervention: Results of a Trial with a Vascular Ultrasound Endpoint

Cited by 2 publications

References 15 publications

Thrombocytopenia following Percutaneous Coronary Intervention

Thrombocytopenia following Percutaneous Coronary Intervention

Safety and Efficacy of Prolonged Use of Unfractionated Heparin After Percutaneous Coronary Intervention

Contact Info

Product

Resources

About